Report highlights high cost of specialty drugs | Appeals court rules against FTC in pay-for-delay case | CMS issues final rule to clamp down on Medicare fraud
April 27, 2012
PCMA SmartBrief
News for the PBM Industry
Featured Story
Report highlights high cost of specialty drugs
Specialty-drug makers have "near-monopoly pricing power," and most of these drugs are covered under medical insurance plans, not pharmacy benefit plans, a study found. "The division of benefit structures makes management of specialty drugs more complex and challenging for payers," the study authors wrote.
Modern Healthcare (subscription required) (4/26) 
LinkedIn Twitter Facebook Google+ Email
Legislative & Regulatory News
Appeals court rules against FTC in pay-for-delay case
A federal appeals court upheld a ruling that a deal between Solvay SA and three other companies to delay generic versions of Solvay's Androgel until 2015 did not violate antitrust laws, as the Federal Trade Commission alleged.
Bloomberg (4/25) 
LinkedIn Twitter Facebook Google+ Email
CMS issues final rule to clamp down on Medicare fraud
The CMS on Tuesday issued a final rule intended to combat Medicare fraud and save the U.S. almost $1.6 billion in costs over a decade. A Government Accountability Office report, however, said that more needs to be done and pressed the CMS to run pre- and post-payment claims evaluations and to address program vulnerabilities.
Healthcare IT News (4/24) 
LinkedIn Twitter Facebook Google+ Email
GOP report: PPACA will raise costs
The PPACA will raise the cost of health care through higher taxes, fees and administrative requirements, according to a report compiled by House Energy and Commerce Committee staff with input from corporate members of a presidential jobs panel. Democrats dismissed the report as partisan and pointed to other corporations that have said the law will not have a negative effect. The report also says some large companies are being urged by consultants to cut health coverage in 2014 and shift workers instead to state-run exchanges.
Reuters (4/26),  The Wall Street Journal (tiered subscription model) (4/26) 
LinkedIn Twitter Facebook Google+ Email
Drug Industry Spotlight
McKesson agrees to $190M settlement in pricing lawsuit
McKesson will pay more than $190 million to settle claims that it issued false reports about drug prices, forcing Medicaid to pay extra for prescription medications. While the company thinks it did not violate the False Claims Act, "this settlement was in the best interest of our employees, customers, suppliers and shareholders," spokesman Kris Fortner said.
Bloomberg Businessweek (4/26) 
LinkedIn Twitter Facebook Google+ Email
Amgen partners with clinical-research organization on biosimilars
Amgen and PRA, a clinical-research organization, agreed to collaborate in a series of late-stage trials to develop the former's biosimilar drugs. The deal makes PRA the exclusive provider of CRO services for Amgen's biosimilars. (4/26) 
LinkedIn Twitter Facebook Google+ Email
Ideas are like rabbits. You get a couple and learn how to handle them, and pretty soon you have a dozen.
John Steinbeck,
American writer
LinkedIn Twitter Facebook Google+ Email
Learn more about PCMA:
Upcoming PCMA Events | PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information